Streetbeat News

Stock Prices

JBLU

JetBlue has updated its Q1 forecasts, showing improvements in ASMs and YoY revenue projections, but expects higher fuel prices. ASMs are now expected to be between -4% and -3%, better than the previous estimate of -6% to -3%. Fuel price per gallon is forecasted to be between $2.93 and $3.03, slightly higher than the prior estimate of $2.87 to $3.02. Year-over-year revenue is anticipated to decline by 7.5% to 4.5%, an improvement from the earlier forecast of a 9% to 5% decrease.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 11:10 am

ETRN

Wells Fargo analyst Michael Blum upgraded Equitrans Midstream (ETRN) from Underweight to Equal-Weight and increased the price target from $10 to $12.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 11:08 am

ADM

ADM's board has authorized an additional $2B share repurchase under its ongoing 200M share repurchase program, set to run through 2024. As of December 31, 2023, about 52 million shares remain for repurchase. Since 2015, ADM has repurchased $8.6 billion of its stock under this program.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 11:07 am

BCDA

BioCardia's stock price increased following the announcement that the Centers for Medicare & Medicaid Services (CMS) approved reimbursement coverage for its CardiAMP cell therapy Phase III heart failure study.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 11:06 am

REFI

Chicago Atlantic Real (NASDAQ:REFI) reported Q4 2023 adjusted EPS of $0.54, surpassing the $0.51 estimate, but missed sales estimates with $14.839M against the expected $16.087M. This represents a slight sales increase of 0.51% from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 11:05 am

LCUT

Lifetime Brands (NASDAQ:LCUT) reported Q4 adjusted EPS of $0.29, missing the $0.33 estimate, and sales of $203.14M, beating the $197.93M estimate. This represents a 17.14% decrease in EPS and a 1.88% decrease in sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 11:03 am

BTAI

BioXcel Therapeutics (BTAI) reported Q4 GAAP EPS of $(0.76), surpassing the $(0.91) estimate, indicating a 61.03% improvement year-over-year. However, their sales of $376.00K fell short of the $710.00K estimate, a 47.04% miss, though it's a 57.98% increase from last year.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 11:03 am

KSS

Kohl's anticipates a net sales growth ranging from a decrease of 1% to an increase of 1% for the fiscal year 2024.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 11:03 am

KSS

Kohl's reported Q4 earnings of $1.67 per share, surpassing the $1.28 estimate, and sales of $5.71B, slightly above the $5.70B estimate. This marks a significant improvement over last year's losses and a slight decrease in sales.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 11:01 am

MSTR

MicroStrategy's stock price increased following an upgrade by TD Cowen, which raised its price target from $1,220 to $1,560.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 11:00 am